6 results on '"Dal Bo Michele"'
Search Results
2. Expression of the transcribed ultraconserved region 70 and the related long non‐coding RNA AC092652.2‐202 has prognostic value in Chronic Lymphocytic Leukaemia.
- Author
-
Bomben, Riccardo, Roisman, Alejandro, D'Agaro, Tiziana, Castellano, Giancarlo, Baumann, Tycho, Delgado, Julio, López‐Guillermo, Armando, Zucchetto, Antonella, Dal‐Bo, Michele, Bravin, Vanessa, Slavutsky, Irma, Vlasova, Anna, Guigó, Roderic, Martin‐Subero, Jose I., Chapaprieta, Vicente, Beekman, Renee, Martin‐García, David, Beà, Sílvia, Salaverria, Itziar, and Aymerich, Marta
- Subjects
NON-coding RNA - Abstract
The article presents a study which explored the possible role of Transcribed Ultraconserved Region (T-UCR) in the pathogenesis of CLL. Topics include potential clinical value of the significantly modulated T-UCRs in two independent cohorts of chronic lymphocytic leukemia (CLL) patients, expression levels of uc.70 and uc.414 in the same cases studied by microarrays and in an independent series of CLL cases, and expression of uc.70-related transcripts using RNAseq data of CLL cases.
- Published
- 2019
- Full Text
- View/download PDF
3. NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types.
- Author
-
D'Agaro, Tiziana, Bittolo, Tamara, Bravin, Vanessa, Dal Bo, Michele, Pozzo, Federico, Bulian, Pietro, Rossi, Francesca M., Zucchetto, Antonella, Degan, Massimo, D'Arena, Giovanni, Chiarenza, Annalisa, Zaja, Francesco, Pozzato, Gabriele, Di Raimondo, Francesco, Rossi, Davide, Gaidano, Gianluca, Del Poeta, Giovanni, Gattei, Valter, and Bomben, Riccardo
- Subjects
GENETIC mutation ,CHRONIC lymphocytic leukemia ,PROTEINS ,GENETIC testing ,LYMPHOCYTIC leukemia - Abstract
The article offers information on clinical relevance of subclonal mutations and mutation types in NOTCH1 mutational status in chronic lymphocytic leukaemia. It mentions the role of NOTCH1 gene mutations in chronic lymphocytic leukaemia (CLL). It discusses the capacity of NOTCH1 mutations to predict both time to first treatment and overall survival.
- Published
- 2018
- Full Text
- View/download PDF
4. B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage.
- Author
-
Dal-Bo, Michele, Del Giudice, Ilaria, Bomben, Riccardo, Capello, Daniela, Bertoni, Francesco, Forconi, Francesco, Laurenti, Luca, Rossi, Davide, Zucchetto, Antonella, Pozzato, Gabriele, Marasca, Roberto, Efremov, Dimitar G., Guarini, Anna, Del Poeta, Giovanni, Foà, Robin, Gaidano, Gianluca, and Gattei, Valter
- Subjects
- *
B cells , *CELL receptors , *IMMUNOGLOBULINS , *GENES , *CHRONIC lymphocytic leukemia , *PROGNOSIS - Abstract
The immunoglobulin heavy chain variable gene ( IGHV) mutational status has been recognized as an important predictor of prognosis in chronic lymphocytic leukaemia (CLL) since 1999. More recently, other features of the B-cell receptor, such as stereotypy, have been identified as capable of refining the prognostic potential of IGHV status in the clinical assessment of CLL patients. In this context, different genes belonging to the IGHV3 subgroup, the most frequently used subgroup in CLL, have been shown to denote disease subsets that either display a bad prognosis (i.e. IGHV3-21, IGHV3-23) or are associated with particularly good clinical outcomes, including a highly stable/indolent clinical course, even prone to spontaneous regression (i.e. IGHV3-72, IGHV3-30). The present review focuses on the molecular and biological features of CLL-expressing specific genes belonging to the IGHV3 subgroup that are known to mark disease subsets with completely different clinical courses, and may be possibly related to CLL pathogenesis via antigen and/or superantigen involvement. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
5. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study.
- Author
-
Bomben, Riccardo, Dal Bo, Michele, Capello, Daniela, Forconi, Francesco, Maffei, Rossana, Laurenti, Luca, Rossi, Davide, Del Principe, Maria Ilaria, Zucchetto, Antonella, Bertoni, Francesco, Rossi, Francesca Maria, Bulian, Pietro, Cattarossi, Ilaria, Ilariucci, Fiorella, Sozzi, Elisa, Spina, Valeria, Zucca, Emanuele, Degan, Massimo, Lauria, Francesco, and Del Poeta, Giovanni
- Subjects
- *
CHRONIC lymphocytic leukemia , *B cells , *IMMUNOGLOBULINS , *MOLECULAR genetics , *CHRONIC diseases - Abstract
A fraction of chronic lymphocytic leukaemia (CLL) cases carry highly homologous B-cell receptors (BCR), i.e. characterized by non-random combinations of immunoglobulin heavy-chain variable ( IGHV) genes and heavy-chain complementarity determining region-3 (HCDR3), often associated with a restricted selection of IGVK/L light chains. Such ‘stereotyped’ BCR occur more frequently in CLL with unmutated (UM) than mutated (M) IGHV genes. We analysed 1426 IG rearrangements (from 1398 CLL cases) by a clustering driven by HCDR3 similarities. Molecular findings were correlated to time-to-treatment (TTT) and presence of known prognosticators. Sixty-nine clusters (319 IG-rearrangements, 22·4%) with stereotyped BCR were identified. Among 30 confirmed clusters (≥3 IG-rearrangements/cluster), we found 14 novel clusters, of which 11 had M IG rearrangements (M clusters) and predominantly (8/11) used IGHV3 subgroup genes. Recurrent cluster-biased amino acid changes were found throughout IGHV sequences of these ‘M clusters’. Regarding clinical outcome: (i) UM CLL from the IGHV1-2/1-3/1-18/1-46/7-4-1/IGKV1-39 cluster had poorer prognosis than UM/M cases, or UM cases using the same IGHV genes but not in clusters; (ii) M CLL from the IGHV3-21/IGLV3-21 cluster had TTT similar to UM CLL, and shorter than M CLL expressing IGHV3-21 but not in cluster. Altogether, our analysis identified additional molecular and clinical features for CLL expressing stereotyped BCR. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
6. HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia
- Author
-
Riccardo Bomben, Paola Omedè, Marta Coscia, Robin Foà, Michele Dal Bo, Mario Boccadoro, Davide Rossi, Gabriele Pozzato, Daniela Magliulo, Giovanni Del Poeta, Valentina Griggio, Rosa Bernardi, Chiara Riganti, Francesca Romana Mauro, Maria Todaro, Gianluca Gaidano, Chiara Salvetti, Massimo Massaia, Joanna Kopecka, Lisa Bonello, Luca Laurenti, Candida Vitale, Thorsten Zenz, Valter Gattei, Monia Marchetti, Ahad Ahmed Kodipad, Griggio, Valentina, Vitale, Candida, Todaro, Maria, Riganti, Chiara, Kopecka, Joanna, Salvetti: Riccardo Bomben, Chiara, Dal Bo, Michele, Magliulo, Daniela, Rossi, Davide, Pozzato, Gabriele, Bonello, Lisa, Marchetti, Monia, Omedè, Paola, Ahmed Kodipad, Ahad, Laurenti, Luca, Del Poeta, Giovanni, Romana Mauro, Francesca, Bernardi, Rosa, Zenz, Thorsten, Gattei, Valter, Gaidano, Gianluca, Foà, Robin, Massaia, Massimo, Boccadoro, Mario, Coscia, Marta, and University of Zurich
- Subjects
RHOA ,Chronic lymphocytic leukemia ,2720 Hematology ,chronic lymphocytic leukaemia ,TP53-disruption ,prognosis ,p53 abnormalities ,Mice ,Phosphatidylinositol 3-Kinases ,0302 clinical medicine ,Tumor Microenvironment ,Chronic, B-Cell ,Cytotoxic T cell ,Chronic ,Patient ,Leukemia ,biology ,CLL microenvironment ,Chemistry ,Hematology ,Lymphocytic ,Editorial ,Von Hippel-Lindau Tumor Suppressor Protein ,Stromal cell ,Patients ,610 Medicine & health ,Chronic Lymphocytic Leukemia ,Hypoxia inducible factor-1a ,ibrutinib ,Article ,03 medical and health sciences ,medicine ,Animals ,Humans ,Protein kinase B ,PI3K/AKT/mTOR pathway ,Tumor microenvironment ,Lymphocytic leukemia ,B-Cell ,medicine.disease ,Hypoxia-Inducible Factor 1, alpha Subunit ,Settore MED/15 ,Leukemia, Lymphocytic, Chronic, B-Cell ,Settore MED/15 - MALATTIE DEL SANGUE ,10032 Clinic for Oncology and Hematology ,biology.protein ,Cancer research ,Tumor Suppressor Protein p53 ,030215 immunology - Abstract
In chronic lymphocytic leukemia (CLL), the hypoxia-inducible factor 1 (HIF-1) regulates the response of tumor cells to hypoxia and their protective interactions with the leukemic microenvironment. In this study, we demonstrate that CLL cells from TP53-disrupted (TP53 dis) patients have constitutively higher expression levels of the α-subunit of HIF-1 (HIF-1α) and increased HIF-1 transcriptional activity compared to the wild-type counterpart. In the TP53 dis subset, HIF-1α upregulation is due to reduced expression of the HIF-1α ubiquitin ligase von Hippel-Lindau protein (pVHL). Hypoxia and stromal cells further enhance HIF-1α accumulation, independently of TP53 status. Hypoxia acts through the downmodulation of pVHL and the activation of the PI3K/AKT and RAS/ERK1-2 pathways, whereas stromal cells induce an increased activity of the RAS/ERK1-2, RHOA/RHOA kinase and PI3K/AKT pathways, without affecting pVHL expression. Interestingly, we observed that higher levels of HIF-1A mRNA correlate with a lower susceptibility of leukemic cells to spontaneous apoptosis, and associate with the fludarabine resistance that mainly characterizes TP53 dis tumor cells. The HIF-1α inhibitor BAY87-2243 exerts cytotoxic effects toward leukemic cells, regardless of the TP53 status, and has anti-tumor activity in Em-TCL1 mice. BAY87-2243 also overcomes the constitutive fludarabine resistance of TP53 dis leukemic cells and elicits a strongly synergistic cytotoxic effect in combination with ibrutinib, thus providing preclinical evidence to stimulate further investigation into use as a potential new drug in CLL.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.